Short sellers in IQV have moved with unusual speed this week, rebuilding positions that were pared before last Tuesday's earnings release — and the pace of that rebuild is the most striking thing about this stock right now.
Short interest climbed 24% over the past five sessions to 3.03% of free float, the sharpest weekly increase since early April. The move erases most of the pre-earnings short covering that pulled SI below 2.4% of float around May 7-8. Bears are effectively back where they were in mid-April, when IQV was trading near its highest short concentration of the past six weeks. The bounce in SI follows a strong Q1 print: IQVIA beat estimates on May 5 and the stock jumped 9.6% on the day, rising a further 8.8% over the following five sessions — exactly the kind of post-earnings rally that creates a fresh entry point for short sellers unwilling to pay up on the way in.
The lending market does not yet reflect conviction. Availability remains very loose, with borrow costs running at just 0.48% annually — firmly within territory where the cost of carrying a short is negligible. The cost to borrow is actually down roughly 14% from a week ago despite the surge in short shares, which implies the supply of lendable stock has absorbed the new demand comfortably. Options positioning tells a more cautious story: the put/call ratio has climbed to 0.98, well above its 20-day average of 0.87 and 1.5 standard deviations higher. That is not an extreme reading by absolute standards — the 52-week high is 2.65 — but the direction of travel since late April is clear, with PCR having drifted higher from the 0.75-0.80 range that prevailed through most of that month. Taken together, the borrow market says shorts are not under pressure; the options market says hedging demand is rising.
The Street broadly remains constructive, though target prices have been coming down. The consensus cluster from major houses — JP Morgan, UBS, Jefferies, Truist — maintains buy-equivalent ratings with targets in the $220-$255 range, but those were all revised lower in February after the Q4 print. The one recent action worth noting: Evercore ISI maintained its Outperform on April 8 but cut its target to $185 from $225, citing concern about the pace of constant-currency growth decelerating from 6.8% to 3.8%. The current mean target is $228.60 against a stock price of $175.06, implying roughly 31% upside — though that gap partly reflects the fact that targets have not yet fully migrated post-Q1. Bulls point to growing momentum in FSP, Real World Evidence, and commercial services, plus improving client decision timelines. Bears flag the risk that any revenue growth print below 5% for 2026 will disappoint a market that has re-rated the stock more cautiously already. The EV/EBITDA multiple at 10.6x and P/E near 13.2x are not demanding, but the company's short score ranks in the 68th percentile of the universe — above average bearish positioning by ORTEX's composite measure.
On the corporate side, IQVIA announced on May 13 an expansion of its strategic collaboration with Kexing Biopharm to accelerate global biosimilar development using AI-enabled capabilities. The deal extends a multi-product program across development and commercialisation — a signal that management is pressing its data and technology platform into life sciences services beyond traditional CRO work. It is a positive headline but unlikely to move near-term financial estimates materially.
Peer performance adds context: CRL fell 9% on the week and RGEN dropped nearly 10%, suggesting sector-level pressure that IQV has so far largely sidestepped with its own 0.8% weekly decline. RVTY was the outlier, gaining 7.6%, while TMO dipped just 1.6%. IQV's relative resilience has likely attracted some of the fresh short interest — bears rotating from weaker names into one that has recently outperformed.
The next formal catalyst is the next quarterly earnings release, for which no date is yet set. Until then, the tension between a rebuilding short base and a still-elevated analyst consensus — with the stock sitting roughly 23% below the mean target — is the dynamic worth tracking.
See the live data behind this article on ORTEX.
Open IQV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
